Involvement of pRB-related p107 protein in the inhibition of S phase progression in response to genotoxic stress.
pRB family pocket proteins consisting of pRB, p107, and p130 are thought to act as a set of growth regulators that inhibit the cell cycle transition from G1 to S phases by virtue of their interaction with E2F transcription factors. When cells are committed to progressing through the cell cycle at the late G1 restriction point, they are hyperphosphorylated by G1 cyclin-cyclin-dependent kinase and are functionally inactivated. Consistent with such a G1 regulatory role, pRB and p130 are abundantly expressed in quiescent cells. In contrast, p107 is present at low levels in the hypophosphorylated form in quiescent cells. As cells progress toward late G1 to S phases, the levels of p107 increase, and the majority become hyperphosphorylated, suggesting a possible role of p107 in post-G1 cell cycle regulation. In this study, we have demonstrated that a nonphosphorylatable and thus constitutively active p107 has the potential to inhibit S phase progression. The levels of the phosphorylation-resistant p107 required for the S phase inhibition are significantly less than those of endogenous p107. We further show herein that the exposure of cells to the DNA-damaging agent, cisplatin, provokes S phase arrest, which is concomitantly associated with the accumulation of hypophosphorylated p107. Furthermore, the S phase inhibitory response to cisplatin is augmented by the ectopic expression of wild type p107, although it is diminished by the adenovirus E1A oncoprotein, which counteracts the pocket protein functions. Because p107 is a major pRB family protein expressed in S phase cells, our results indicate that p107 participates in an inhibition of cell cycle progression in response to DNA damage in S phase cells.
Division of Molecular Oncology, Institute for Genetic Medicine, Department of Medicine II, School of Medicine, Hokkaido University, Kita-ku, Sapporo 060, Japan.
T
T
Kondo
H
H
Higashi
H
H
Nishizawa
S
S
Ishikawa
S
S
Ashizawa
M
M
Yamada
Z
Z
Makita
T
T
Koike
M
M
Hatakeyama
D019943:Amino Acid Substitution; D000818:Animals; D019556:COS Cells; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D017077:Culture Media, Conditioned; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D051379:Mice; D016297:Mutagenesis, Site-Directed; D015739:Nocodazole / Q000494:pharmacology; D009687:Nuclear Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000378:metabolism*; D050720:Retinoblastoma-Like Protein p107; D016196:S Phase; D017384:Sequence Deletion; D012694:Serine; D013912:Threonine; D014162:Transfection; D014407:Tumor Cells, Cultured
D017077:Culture Media, Conditioned; D007377:Interleukin-3; D009687:Nuclear Proteins; C493844:RBL1 protein, human; C489485:Rbl1 protein, mouse; D011994:Recombinant Proteins; D016160:Retinoblastoma Protein; D050720:Retinoblastoma-Like Protein p107; D013912:Threonine; D012694:Serine; D015739:Nocodazole; D006918:Hydroxyurea